Hengrui-linked HRS9531 obesity Phase 3 grows to 675 patients as trial opens enrollment
Fujian Shengdi's oral HRS9531 confirmatory trial enlarged its target by 58.8% and started recruiting, feeding a 52-week weight-loss readout that will test the drug's Phase 2 result at Phase 3 scale.
Executive Summary
- A Phase 3 confirmatory trial of Fujian Shengdi's oral HRS9531 opened for enrollment and grew its target patient count by more than half, with its completion window extending a few months into the future.
- The larger trial is the vehicle for testing whether HRS9531's earlier weight-loss result holds up at registrational scale, the step that determines whether the drug can compete with GLP-1 receptor agonists already advancing through late-stage obesity programs.
- HRS9531's oral formulation already showed a weight-loss effect against placebo in an earlier-phase trial, giving this larger study a concrete benchmark to reproduce rather than a novel hypothesis to prove.
- The obesity field is dense with GLP-1 receptor-targeting molecules in Phase 3, from oral small molecules to injectable peptides, making differentiation on oral convenience and effect size the bar this trial will be read against.
The trial
NCT07670884 is a randomized, quadruple-masked, two-arm Phase 3 study testing HRS9531 tablets against placebo in overweight or obese adults with a body mass index of 28 kg/m2 or higher, or 24 kg/m2 or higher with a weight-related comorbidity. Its registry record moved from Not yet recruiting to Recruiting on July 21, 2026, the same day its enrollment target rose from 425 to 675 patients and its primary completion date shifted from July 1, 2027 to October 31, 2027. The trial is run entirely in China and is designated registrational. NCT07670884A Clinical Study to Evaluate the Efficacy and Safety of HRS9531 Tablets in Overweight or Obese SubjectsNCT07670884
What it will measure
The primary endpoint is percentage change from baseline in body weight after 52 weeks of treatment, alongside the proportion of subjects losing at least 5% of baseline body weight over the same period. Secondary measures track BMI, waist circumference, blood pressure, lipids, glucose, insulin, and adverse events through 57 weeks, the standard battery for a registrational obesity trial. No results have posted for this study, which is consistent with a trial that only began recruiting this month. NCT07670884A Clinical Study to Evaluate the Efficacy and Safety of HRS9531 Tablets in Overweight or Obese SubjectsNCT07670884
The precedent it must match
HRS9531's earlier oral Phase 2 trial, NCT06841445, completed in China and reported topline results showing mean weight loss up to 12.1% with 25 mg and 50 mg doses against 2.3% for placebo at Week 26, meeting its primary endpoint. That result gives this larger Phase 3 a concrete band to reproduce at 52 weeks and at scale, rather than a first attempt to establish that HRS9531 lowers body weight at all. A companion Phase 3 trial, NCT07285902, is separately comparing an injectable HRS9531 formulation against semaglutide in obesity and has finished recruiting. NCT07670884A Clinical Study to Evaluate the Efficacy and Safety of HRS9531 Tablets in Overweight or Obese SubjectsNCT07670884
The enrollment increase in context
The 58.8% enrollment increase and the roughly four-month shift in primary completion date are the kind of adjustment a sponsor makes when finalizing a registrational protocol at the start of recruitment, not a signal of trouble: the trial has not yet enrolled a single reported patient under the revised target, and Fujian Shengdi has completed all 25 of its prior trials on record, with no terminations. The obesity field around HRS9531 is dense with GLP-1 receptor-targeting programs, including Eli Lilly's orforglipron, Roche's enicepatide, AstraZeneca's elecoglipron, and Novo Nordisk's CagriSema, all in Phase 3 testing in obesity, alongside peptide incumbents tirzepatide and semaglutide already marketed for weight management. Against that field, an oral small molecule reproducing double-digit percentage weight loss at 52 weeks in a larger, adequately powered population would be the result that keeps HRS9531 in contention with the injectable GLP-1 class on convenience and effect size.
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.